Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Has $2.55 Million Position in IDEXX Laboratories, Inc. (IDXX)

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,695 shares of the company’s stock after selling 454 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in IDEXX Laboratories were worth $2,549,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Redpoint Investment Management Pty Ltd grew its position in IDEXX Laboratories by 10.9% in the 2nd quarter. Redpoint Investment Management Pty Ltd now owns 5,865 shares of the company’s stock worth $1,278,000 after purchasing an additional 577 shares during the period. Stevens Capital Management LP grew its position in IDEXX Laboratories by 14.4% in the 2nd quarter. Stevens Capital Management LP now owns 24,138 shares of the company’s stock worth $5,261,000 after purchasing an additional 3,030 shares during the period. Swiss National Bank grew its position in IDEXX Laboratories by 3.1% in the 2nd quarter. Swiss National Bank now owns 288,600 shares of the company’s stock worth $62,897,000 after purchasing an additional 8,800 shares during the period. Schwab Charles Investment Management Inc. grew its position in IDEXX Laboratories by 10.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 356,872 shares of the company’s stock worth $77,777,000 after purchasing an additional 34,590 shares during the period. Finally, Russell Investments Group Ltd. grew its position in IDEXX Laboratories by 4.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 41,371 shares of the company’s stock worth $9,008,000 after purchasing an additional 1,574 shares during the period. 91.19% of the stock is owned by institutional investors.

A number of equities research analysts have commented on IDXX shares. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, June 15th. Credit Suisse Group lifted their target price on shares of IDEXX Laboratories from $209.00 to $228.00 and gave the stock an “outperform” rating in a research report on Friday, June 1st. Stifel Nicolaus lifted their target price on shares of IDEXX Laboratories from $225.00 to $260.00 and gave the stock a “buy” rating in a research report on Tuesday, July 10th. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. Finally, ValuEngine raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. IDEXX Laboratories presently has a consensus rating of “Buy” and an average price target of $244.00.

In other news, insider Giovani Twigge sold 1,626 shares of IDEXX Laboratories stock in a transaction on Tuesday, May 29th. The shares were sold at an average price of $204.37, for a total transaction of $332,305.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bruce L. Claflin purchased 415 shares of the company’s stock in a transaction dated Friday, August 3rd. The shares were acquired at an average price of $242.12 per share, for a total transaction of $100,479.80. Following the purchase, the director now directly owns 1,415 shares in the company, valued at $342,599.80. The disclosure for this purchase can be found here. Insiders have sold a total of 72,230 shares of company stock worth $17,591,265 in the last quarter. Corporate insiders own 2.56% of the company’s stock.

Shares of IDEXX Laboratories stock opened at $249.50 on Monday. The firm has a market cap of $21.60 billion, a PE ratio of 76.07, a price-to-earnings-growth ratio of 2.28 and a beta of 0.69. IDEXX Laboratories, Inc. has a 1-year low of $146.09 and a 1-year high of $252.49. The company has a debt-to-equity ratio of -14.77, a quick ratio of 0.73 and a current ratio of 0.96.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Wednesday, August 1st. The company reported $1.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.17 by $0.06. The business had revenue of $580.75 million for the quarter, compared to analysts’ expectations of $574.68 million. IDEXX Laboratories had a net margin of 14.50% and a negative return on equity of 703.80%. The company’s revenue was up 14.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.87 EPS. equities analysts expect that IDEXX Laboratories, Inc. will post 4.18 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Story: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply